PMID- 33945128
OWN - NLM
STAT- MEDLINE
DCOM- 20220104
LR  - 20220531
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 1347
DP  - 2021
TI  - Aldo Keto Reductases AKR1B1 and AKR1B10 in Cancer: Molecular Mechanisms and 
      Signaling Networks.
PG  - 65-82
LID - 10.1007/5584_2021_634 [doi]
AB  - Deregulation of metabolic pathways has increasingly been appreciated as a major 
      driver of cancer in recent years. The principal cancer-associated alterations in 
      metabolism include abnormal uptake of glucose and amino acids and the 
      preferential use of metabolic pathways for the production of biomass and 
      nicotinamide adenine dinucleotide phosphate (NADPH). Aldo-keto reductases (AKRs) 
      are NADPH dependent cytosolic enzymes that can catalyze the reduction of carbonyl 
      groups to primary and secondary alcohols using electrons from NADPH. Aldose 
      reductase, also known as AKR1B1, catalyzes the conversion of excess glucose to 
      sorbitol and has been studied extensively for its role in a number of diabetic 
      pathologies. In recent years, however, high expression of the AKR1B and AKR1C 
      family of enzymes has been strongly associated with worse outcomes in different 
      cancer types. This review provides an overview of the catalysis-dependent and 
      independent data emerging on the molecular mechanisms of the functions of AKRBs 
      in different tumor models with an emphasis of the role of these enzymes in 
      chemoresistance, inflammation, oxidative stress and epithelial-to-mesenchymal 
      transition.
CI  - (c) 2021. Springer Nature Switzerland AG.
FAU - Banerjee, Sreeparna
AU  - Banerjee S
AUID- ORCID: 0000-0003-4596-6768
AD  - Department of Biological Sciences, Orta Dogu Teknik Universitesi (ODTU/METU), 
      Ankara, Turkey. banerjee@metu.edu.tr.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
RN  - 53-59-8 (NADP)
RN  - EC 1.1.1.- (AKR1B10 protein, human)
RN  - EC 1.1.1.- (Aldo-Keto Reductases)
RN  - EC 1.1.1.21 (AKR1B1 protein, human)
RN  - EC 1.1.1.21 (Aldehyde Reductase)
SB  - IM
MH  - *Aldehyde Reductase/genetics
MH  - *Aldo-Keto Reductases/genetics
MH  - Catalysis
MH  - Drug Resistance, Neoplasm
MH  - Epithelial-Mesenchymal Transition
MH  - Humans
MH  - Inflammation
MH  - NADP
MH  - *Neoplasms/genetics
MH  - Oxidative Stress
OTO - NOTNLM
OT  - Aldo keto reductases
OT  - Cancer
OT  - Chemoresistance
OT  - Epithelial-to-mesenchymal transition
OT  - Inflammation
OT  - Oxidative stress
EDAT- 2021/05/05 06:00
MHDA- 2022/01/05 06:00
CRDT- 2021/05/04 12:41
PHST- 2021/05/05 06:00 [pubmed]
PHST- 2022/01/05 06:00 [medline]
PHST- 2021/05/04 12:41 [entrez]
AID - 10.1007/5584_2021_634 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2021;1347:65-82. doi: 10.1007/5584_2021_634.